Showing results (1-10 of 30) with videos related to
Sort By:
Pageof 3
Thrombosis and Haemostasis|November 5, 2005
Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic diseaseJudith Leurs, Dirk HendriksFrontiers in Bioscience (Landmark Edition)|May 31, 2011
An update on the role of carboxypeptidase U (TAFIa) in fibrinolysisEvelien Heylen, Johan Willemse, Dirk HendriksAnalytical Biochemistry|April 2, 2005
Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrateJohan Willemse, Judith Leurs, Robert Verkerk, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|October 30, 2008
Carboxypeptidase M: Multiple alliances and unknown partnersKathleen Deiteren, Dirk Hendriks, Simon Scharpé, et al.International Journal of Molecular Sciences|January 22, 2021
Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?Karen Claesen, Joachim C Mertens, Dorien Leenaerts, et al.Analytical Biochemistry|April 8, 2010
Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assayEvelien Heylen, Sebastiaan Van Goethem, Koen Augustyns, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|November 27, 2012
Carboxypeptidase M in apoptosis, adipogenesis and cancerCatherine J Denis, Kathleen Deiteren, Dirk Hendriks, et al.Analytical Biochemistry|September 8, 2009
Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasmaEvelien Heylen, Sebastiaan Van Goethem, Johan Willemse, et al.Thrombosis and Haemostasis|February 8, 2003
Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasmaJudith Leurs, Britt-Marie Wissing, Viveca Nerme, et al.Pharmaceutics|October 23, 2021
Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a Mouse Model of Advanced AtherosclerosisKaren Claesen, Lynn Roth, Joachim C Mertens, et al.Pageof 3